Sue Hughes

2 weeks ago | medscape.com | Sue Hughes

In women with signs of ischemia but no obstructive coronary artery disease (OCAD), intensive medical therapy did not reduce the first occurrence of a major cardiovascular event in the WARRIOR trial, but the trial was underpowered to show a definitive result. "This is a neutral trial and should not be considered a negative trial," said study investigator Eileen Handberg, PhD, professor of medicine at the University of Florida in Orlando.

3 weeks ago | medscape.com | Sue Hughes

Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at least 6 months of anticoagulant treatment after a clot, and results in a lower rate of clinically relevant bleeding, the API-CAT trial shows.

3 weeks ago | medscape.com | Sue Hughes

Semaglutide, a GLP-1 agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, the drug significantly improved walking distance, symptoms like pain, and quality of life in patients with symptomatic PAD and type 2 diabetes. It was also associated with a reduction in disease progression and the use of rescue therapy and an improvement in ankle brachial index scores.

1 month ago | espanol.medscape.com | Sue Hughes

Un análisis de sangre realizado en un entorno prehospitalario puede distinguir rápidamente entre un ictus isquémico y hemorrágico, lo que potencialmente facilita un tratamiento más rápido y específico.[1] La prueba mide los niveles de proteína ácida fibrilar glial (GFAP), una proteína específica del cerebro que se libera en el torrente sanguíneo cuando las células cerebrales se dañan o destruyen. Ya se utiliza para evaluar la lesión cerebral traumática.

2 months ago | medscape.com | Sue Hughes

A blood test conducted in a prehospital setting may rapidly distinguish between ischemic and hemorrhagic stroke, potentially facilitating more rapid, targeted treatment. The test measures the levels of glial fibrillary acidic protein (GFAP), a protein specific to the brain which is released into the bloodstream when brain cells are damaged or destroyed. It is already used to assess traumatic brain injury.